Integrating WHO 2001-2008 criteria for the diagnosis of Myelodysplastic Syndrome (MDS): A case-case analysis of benzene exposure

被引:25
作者
Irons, Richard D. [1 ,2 ,3 ,4 ,5 ]
Gross, Sherilyn A. [2 ,4 ]
Le, Anh [4 ]
Wang, Xiao Qin [2 ,7 ]
Chen, Yan [2 ]
Ryder, John [2 ,5 ]
Schnatter, A. Robert [6 ]
机构
[1] Cinpathogen Inc, Boulder, CO 80303 USA
[2] Fudan Univ, Fudan Cinpathogen Clin & Mol Res Ctr, Inst Biomed Sci, Shanghai 200433, Peoples R China
[3] Cinpathogen Inc, Shanghai, Peoples R China
[4] Univ Colorado, Mol Toxicol & Environm Hlth Sci Program, Sch Pharm, Denver, CO 80202 USA
[5] Univ Colorado, Dept Pathol, Sch Med, Denver, CO 80202 USA
[6] ExxonMobil Biomed Sci Inc, Annandale, NJ 08801 USA
[7] Fudan Univ, Huashan Hosp, Shanghai 200433, Peoples R China
关键词
Myelodysplasia; Benzene; Eosinophil dysplasia; Immune-mediated; Cytogenetic abnormalities; COLONY-STIMULATING FACTOR; ACUTE MYELOID-LEUKEMIA; DOSE-DEPENDENT HYPOPLOIDY; HUMAN CELL-LINE; BONE-MARROW; T-CELLS; ERYTHROID HYPOPLASIA; ORGANIC-SOLVENTS; PROGENITOR CELLS; APLASTIC-ANEMIA;
D O I
10.1016/j.cbi.2009.11.016
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We characterized the prevalence of hematopoietic and lymphoid disease for 2923 consecutive patients presenting at 29 hospitals from August 2003 to June 2007. Diagnoses were made in our laboratory using WHO criteria based on morphologic, immunophenotypic, cytogenetic. FISH and molecular data. A total of 611 subjects (322 males/289 females) were prospectively diagnosed with MDS using WHO (2001) criteria. Update and re-evaluation of cases using MDS (2008) criteria resulted in 649 MDS cases. Using WHO (2008) criteria, refractory cytopenia with multilineage dysplasia (RCMD) accounted for 68% of total cases, refractory anemia with excess blasts (RAEB), 16.3%; refractory anemia (RA), 6.5%; refractory cytopenia with unilineage dysplasia (RCUD), 4%; and MDS-unclassifiable (MDS-U), 4.5%. Subjects were administered questionnaires and information on previous disease, work histories and exposures to potential etiologic agents such as benzene (BZ) was obtained. A total of 80/649 (13.2%) were determined to have some BZ exposure. The frequency of clonal cytogenetic abnormalities in all MDS was 30%, the most common being +8 > del(20)q > del(7q) > del(5q), while the analogous frequency in BZ-exposed cases was only 24%. To further investigate the characteristics of MDS associated with BZ, we identified a subset of cases with high BZ exposure. These BZ signal cases were each matched by age and gender to two cases with no known BZ exposure. When contrasting BZ signal cases vs matched cases with no BZ exposure, we found a high odds ratio (OR) for the WHO subtype MDS-U (OR = 11.1), followed by RAEB and RCUD (OR = 1), RA (OR = 0.7) and RCMD (OR = 0.6). Multilineage dysplasia with abnormal eosinophils (MDS-Eo) was strongly associated with BZ exposure, whereas the relative risk of clonal cytogenetic abnormalities was reduced for high BZ-exposed cases (OR = 0.5). These findings are strongly indicative that MDS subtypes are influenced by BZ exposure, and taken together with previous studies, the features of MDS-Eo suggest that altered immune regulation plays a major role in the pathogenesis of MDS following chronic exposure to BZ. (C) 2009 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:30 / 38
页数:9
相关论文
共 48 条
[1]   Exposure assessment for case-control and case-case epidemiology studies based in Shanghai China: Summary of methods and results [J].
Armstrong, T. ;
Liang, Y. ;
Zhou, Y. ;
Bowes, S. ;
Wong, O. ;
Fu, H. ;
Schnatter, A. ;
Zhang, C. .
CHEMICO-BIOLOGICAL INTERACTIONS, 2010, 184 (1-2) :286-289
[2]  
BAINES P, 1988, EXP HEMATOL, V16, P785
[3]   Core-binding factor-β positive acute myeloid leukaemia cells induce T-cell responses [J].
Banat, GA ;
Ihlow, K ;
Usluoglu, N ;
Hoppmann, S ;
Hoeck, M ;
Pralle, H .
BRITISH JOURNAL OF HAEMATOLOGY, 2003, 123 (05) :819-829
[4]   Myelodysplastic syndrome - an example of misguided immune surveillance? [J].
Barrett, AJ .
LEUKEMIA RESEARCH, 2004, 28 (11) :1123-1124
[5]  
Biesma DH, 1997, CANCER-AM CANCER SOC, V79, P1548, DOI 10.1002/(SICI)1097-0142(19970415)79:8<1548::AID-CNCR16>3.0.CO
[6]  
2-Y
[7]   Myelodysplastic syndromes - Coping with ineffective hematopoiesis [J].
Cazzola, M ;
Malcovati, L .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (06) :536-538
[8]   Clinical and cytogenetic features of 508 Chinese patients with myelodysplastic syndrome and comparison with those in Western countries [J].
Chen, B ;
Zhao, WL ;
Jin, J ;
Xue, YQ ;
Cheng, X ;
Chen, XT ;
Cui, J ;
Chen, ZM ;
Cao, Q ;
Yang, G ;
Yao, Y ;
Xia, HL ;
Tong, JH ;
Li, JM ;
Chen, J ;
Xiong, SM ;
Shen, ZX ;
Waxman, S ;
Chen, Z ;
Chen, SJ .
LEUKEMIA, 2005, 19 (05) :767-775
[9]   Distinctive gene expression profiles of CD34 cells from patients with myelodysplastic syndrome characterized by specific chromosomal abnormalities [J].
Chen, GB ;
Zeng, WH ;
Miyazato, A ;
Billings, E ;
Maciejewski, JP ;
Kajigaya, S ;
Sloand, EM ;
Young, NS .
BLOOD, 2004, 104 (13) :4210-4218
[10]   MORPHOLOGIC, IMMUNOLOGICAL AND CYTOGENETIC STUDIES IN ACUTE MYELOID-LEUKEMIA FOLLOWING OCCUPATIONAL EXPOSURE TO PESTICIDES AND ORGANIC-SOLVENTS [J].
CUNEO, A ;
FAGIOLI, F ;
PAZZI, I ;
TALLARICO, A ;
PREVIATI, R ;
PIVA, N ;
CARLI, MG ;
BALBONI, M ;
CASTOLDI, G .
LEUKEMIA RESEARCH, 1992, 16 (08) :789-796